Bioequivalence study of Azithromycin 250 mg
Not Applicable
Completed
- Conditions
- Healthy volunteers.
- Registration Number
- IRCT20200623047902N8
- Lead Sponsor
- Sanamed pharma company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28)
Informed consent
Age (18-55 years old)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcoholism and Narcoticism
History of allergy to Azithromycin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Azithromycin 250 mg capsule in healthy volunteers as studied in IRCT20200623047902N8?
How does Sanamed's Azithromycin 250 mg capsule compare to originator brands in terms of bioavailability and pharmacokinetics?
Are there specific biomarkers that correlate with Azithromycin response in healthy populations for bioequivalence studies?
What adverse events are associated with Azithromycin 250 mg formulations in clinical trials and how are they managed?
How does the bioequivalence of Sanamed's Azithromycin capsule relate to other macrolide antibiotics in therapeutic use?